Safety and efficacy of intracranial radiotherapy under immunotherapy against CNS metastases of extensive-stage small cell lung cancer in the real-world setting.

Safety and efficacy of intracranial radiotherapy under immunotherapy against CNS metastases of extensive-stage small cell lung cancer in the real-world setting. - SERIAL study

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000041879

Enrollment

Registered

2020-10-01

Start date

2021-01-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Lung Cancer

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1) Age of 20 years old or older 2) Advanced or postoperative recurrence small cell lung cancer 3) Intracranial radiation therapy is planned within 8 weeks after or during the platinum doublet + ICI therapy, or ICI maintenance therapy 4) Consent is obtained in writing regarding participation in this study

Exclusion criteria

Exclusion criteria: 1) The cases which the attending physician has determined ineligible

Design outcomes

Primary

Measure	Time frame
Safety(Grade 3 or higher non-hematological toxicity )	—

Countries

Japan

Contacts

Public ContactAsuka Okada

Saiseikai Suita Hospital, Osaka Department of Respiratory Medicine

aska_517@icloud.com06-6382-1521

Outcome results